Miami-based DermaSensor named Larry Anderson as its new chief commercial officer. Dr. Vivien Nguyen also joins as director of medical affairs, while the company promoted Ryan Freiden to COO.
Anderson previously served as VP of sales for Acessa Health, which Hologic acquired. He also held roles at Ethicon, Interlace Medical, Hologic and BG Medical.
“It gives me great pleasure to introduce Larry Anderson as our chief commercial officer,” DermaSensor CEO Cody Simmons said in a news release. “Larry has extensive commercial experience in the medical device field with a strong track record of successfully building teams and launching new technologies.”
Nguyen joins with nearly a decade of experience in medical devices and pharmaceuticals. She held roles at Incyte, Novartis, Suneva Medical and OptumRx.
“I’m also excited to announce that Dr. Vivien Nguyen has joined DermaSensor as our director of medical affairs, as it will be key for her team to provide effective medical and scientific education and awareness of our first-in-class product to the medical community,” Simmons said.
Frieden long served as DermaSensor’s VP of product and operations. He said in the release that he led four-year product development efforts in the role.
“I am hopeful that we will soon be able to equip US physicians with our device as we have been doing abroad,” said Freiden. “I look forward to leading the company’s operational expansion through this next phase of development, and I am very grateful to the investors that have provided a total of $27 million to enable us to execute on our goal of enabling all frontline providers to access our first-in-class, FDA breakthrough device.”
What DermaSensor does
DermaSensor’s handheld device uses a form of optical spectroscopy called elastic scattering spectroscopy (ESS). It takes noninvasive samples of tissue, capturing cellular-level information. The technology uses hundreds of wavelengths of light in a manner similar to how sonar uses sound.
The company won the MedTech Innovator Mid-Stage Companies Pitch Event at DeviceTalks Boston in May. It recently raised $10 million as it prepares for a commercial launch in the U.S.
DermaSensor’s technology could become the first device cleared by the FDA to assist primary care physicians in evaluating skin cancer.
